| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Likely targets folate receptors and enzymes (e.g., dihydrofolate reductase), similar to folic acid, but the methyl ester modification may alter binding affinity and cellular uptake.
|
|---|---|
| ln Vitro |
Modulates one-carbon metabolism, potentially influencing neurotransmitter synthesis; may have antidepressant-like effects by normalizing folate-related pathways in the brain.
|
| ln Vivo |
Shown to be effective in animal models of depression, possibly by increasing bioavailability of active folate metabolites in the CNS and modulating monoamine neurotransmitters.
|
| Enzyme Assay |
Folate binding assay: incubate folate receptor with radiolabeled folic acid and varying concentrations of folic acid methyl ester (1 nM-100 microM), measure bound radioactivity to calculate inhibition constant.
|
| Cell Assay |
Cellular uptake assay: incubate folate receptor-expressing cells (e.g., KB cells) with fluorescently labeled folic acid methyl ester (0.1-50 microM) for 2h at 37degC, measure intracellular fluorescence by flow cytometry.
|
| Animal Protocol |
Chronic unpredictable mild stress (CUMS) model in rats: oral administration of folic acid methyl ester (1-10 mg/kg) daily for 4 weeks; measure sucrose preference and forced swim test immobility.
|
| ADME/Pharmacokinetics |
Rapidly absorbed after oral administration; metabolized to active folate species (e.g., 5-methyltetrahydrofolate) via esterases and one-carbon metabolism; urinary excretion as folate metabolites.
|
| Toxicity/Toxicokinetics |
Considered safe; based on folic acid profile, very low toxicity; no adverse effects reported at research doses; generally recognized as safe for nutritional applications.
|
| References |
[1]. Vuckovis, et al. Compositions and methods for treating depression. World Intellectual Property Organization, WO2018144088 A1. 2018-08-09.
|
| Additional Infomation |
This compound is for research use only, not for clinical therapy. It may serve as a stable analog for studying folate metabolism and neuropsychiatric conditions like depression. No approved therapeutic status.
|
| Molecular Formula |
C20H21N7O6
|
|---|---|
| Exact Mass |
455.155
|
| CAS # |
1348988-65-7
|
| PubChem CID |
136502003
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
33
|
| Complexity |
783
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
COC(=O)[C@H](CCC(=O)O)NC(=O)C1=CC=C(C=C1)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N
|
| InChi Key |
YIVGBIWFBUNYLC-ZDUSSCGKSA-N
|
| InChi Code |
InChI=1S/C20H21N7O6/c1-33-19(32)13(6-7-14(28)29)25-17(30)10-2-4-11(5-3-10)22-8-12-9-23-16-15(24-12)18(31)27-20(21)26-16/h2-5,9,13,22H,6-8H2,1H3,(H,25,30)(H,28,29)(H3,21,23,26,27,31)/t13-/m0/s1
|
| Chemical Name |
(4S)-4-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-methoxy-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
